BioNexus Gene Enters Partnership With BirchBioMed To Lead Birch's $10M Funding Round Through Equity Investment, Collaboration

BioNexus Gene Lab Corp (NASDAQ:BGLC, "BGLC", or the "Company")), today announced that it has entered into a non-binding Strategic Partnership Term Sheet with BirchBioMed Inc. ("Birch"), a Canadian biopharmaceutical company developing regenerative treatments for organ fibrosis, topical scarring and autoimmune diseases.

Under the non-binding term sheet, BGLC would lead Birch's USD $10 million upcoming financing round through a strategic equity investment and collaboration to accelerate commercialization of Birch's FS2 (kynurenic acid) topical platform in Southeast Asia. The partnership is designed to combine BGLC's regional market access and infrastructure with Birch's novel science in dermal regeneration and fibrosis control.